|
(単位:千ドル)
|
2Q11
|
3Q11
|
1Q12
|
2Q12
|
3Q12
|
1Q13
|
2Q13
|
3Q13
|
1Q14
|
2Q14
|
3Q14
|
1Q15
|
2Q15
|
3Q15
|
1Q16
|
2Q16
|
3Q16
|
1Q17
|
2Q17
|
3Q17
|
1Q18
|
2Q18
|
3Q18
|
1Q19
|
2Q19
|
3Q19
|
1Q20
|
2Q20
|
3Q20
|
1Q21
|
2Q21
|
3Q21
|
1Q22
|
2Q22
|
3Q22
|
1Q23
|
2Q23
|
3Q23
|
|
研究開発費
|
1,392
|
1,016
|
940
|
1,307
|
1,374
|
1,213
|
2,590
|
3,021
|
3,242
|
3,051
|
2,385
|
2,303
|
2,546
|
2,432
|
2,568
|
2,795
|
3,294
|
3,384
|
3,211
|
2,928
|
1,398
|
1,026
|
928
|
1,110
|
1,716
|
1,459
|
1,051
|
940
|
1,040
|
1,012
|
928
|
1,118
|
1,431
|
1,349
|
1,168
|
1,381
|
715
|
703
|
|
営業費用
|
2,527
|
2,213
|
2,460
|
2,755
|
2,840
|
2,851
|
5,072
|
5,406
|
5,071
|
4,739
|
4,185
|
5,511
|
5,760
|
5,869
|
5,567
|
5,786
|
5,878
|
6,669
|
6,926
|
6,316
|
4,832
|
2,812
|
2,113
|
2,778
|
3,248
|
2,732
|
2,428
|
2,195
|
2,283
|
2,224
|
2,310
|
2,453
|
2,665
|
2,730
|
2,800
|
2,488
|
2,085
|
2,828
|
|
営業利益
|
-2,528
|
-2,214
|
-2,461
|
-2,756
|
-2,841
|
-2,852
|
-5,073
|
-5,407
|
-5,071
|
-4,739
|
-4,185
|
-5,511
|
-5,760
|
-5,869
|
-5,567
|
-5,786
|
-5,878
|
-6,669
|
-6,926
|
-6,316
|
-4,832
|
-2,812
|
-2,113
|
-2,778
|
-3,248
|
-2,732
|
-2,428
|
-2,195
|
-2,283
|
-2,224
|
-2,310
|
-2,453
|
-2,665
|
-2,730
|
-2,800
|
-2,488
|
-2,085
|
-2,828
|
|
純利益
|
-1,371
|
3,067
|
3,149
|
2,200
|
8,028
|
-13,327
|
-14,286
|
-5,437
|
-5,103
|
-3,646
|
-1,213
|
-15,830
|
-10,443
|
-2,308
|
-6,623
|
-5,184
|
-
|
-
|
-6,340
|
-9,350
|
-4,784
|
-12,939
|
-3,175
|
-2,635
|
-3,144
|
-2,679
|
-2,414
|
-2,189
|
-2,279
|
-2,223
|
-2,309
|
-2,451
|
-2,655
|
-2,719
|
-2,755
|
-2,300
|
-1,937
|
-2,697
|
|
一株あたり利益
|
-
|
0.06
|
0.05
|
0.03
|
0.12
|
-0.2
|
-0.2
|
-0.07
|
-
|
-0.04
|
-0.01
|
-0.64
|
-0.39
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-1.94
|
-1.97
|
-1.98
|
-0.85
|
-0.62
|
-0.87
|
|
希薄化後一株あたり利益
|
-
|
0.06
|
0.05
|
0.03
|
0.11
|
-0.2
|
-0.2
|
-0.07
|
-
|
-0.04
|
-0.01
|
-0.64
|
-0.39
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-1.94
|
-1.97
|
-1.98
|
-0.85
|
-0.62
|
-0.87
|
|
EBITDA
|
-
|
-
|
|
-
|
-
|
|
-
|
-
|
|
-
|
-
|
|
-
|
-
|
|
-
|
-
|
|
-
|
-
|
|
-
|
-
|
|
-
|
-
|
|
-
|
-
|
|
-
|
-
|
|
-
|
-
|
|
-
|
-
|